RxDoctor Payments Data

Syed Rahman, MD

Geriatric Medicine · Henderson, NVNPI 1427169986

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.9% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Exact Sciences at 26.2% of the total.

$339in general payments, 2019–2025

Across 16 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$89
  • Boston Scientific$58
  • Bayer$33
  • Amgen$28
  • AstraZeneca$26
  • Medtronic$22
  • plus $83 from 6 others

What the payments were for

  • Speaking & faculty fees$144%
  • Food & beverage$32596%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$339 in reported general payments places this provider in the 55th percentile of 36 geriatric medicine providers in Nevada.

See all geriatric medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$314,388
Medicare patients
417
Services billed
2,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban421$148,602
OzempicSemaglutide19$20,128
FarxigaDapagliflozin Propanediol34$15,244
MounjaroTirzepatide11$15,064
JanuviaSitagliptin Phosphate15$14,968
SymbicortBudesonide/Formoterol Fumarate33$7,865
Albuterol Sulfate HfaAlbuterol Sulfate204$6,497
Atorvastatin Calcium673$6,308
ArexvyRsvpref3 Antigen/As01e/Pf20$5,999
Gabapentin424$5,937
BelsomraSuvorexant20$4,609
Memantine Hcl99$3,970
Divalproex Sodium84$3,809
LokelmaSodium Zirconium Cyclosilicate19$3,656
Lantus SolostarInsulin Glargine,hum.Rec.Anlog83$3,549

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$148,602421 claims
AstraZenecaFarxiga, Symbicort, Lokelma$26$26,76586 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 36 geriatric medicine providers in Nevada.

Other geriatric medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →